Influence of amygdalin on PDG, IGF and PDGFR expression in HSC-T6 cells

The aim of the present study was to elucidate the mechanism of amygdalin treatment on reducing liver fibrosis by investigating its role in regulating the expression level of platelet-derived growth factor (PDGF), insulin-like growth factor (IGF) and PDGF receptor (PDGFR) in the hepatic stellate cell (HSC)-T6 line. HSC-T6 cells were used as an in vitro model and randomly assigned into four groups: control, high-dose amygdalin, mid-dose amygdalin and low-dose amygdalin. Following amygdalin treatment, compared with the control, a high dose of amygdalin significantly suppressed the mRNA expression of PDGF and IGF (each P<0.05), whereas moderate and low doses showed no significant effect, relatively low doses of amygdalin are not sufficient to transfer signals to its receptor. The high-dose amygdalin and low-dose amygdalin displayed suppressed protein expression of PDGF at 24, 48 and 72 h, with the high-dose group exhibiting the most marked suppression at all three time points. By reducing the transcription of PDGF and IGF mRNA and the expression of PDGF protein, amygdalin decreased the synthesis and release of PDGF and IGF, thereby reducing the influence of PDGF and IGF on HSCs, thus protecting the liver from fibrosis.